Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Completed

CT.gov ID

NCT01624766

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arms

104.2

Actual Duration (Months)

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or aren't responding to treatment. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and the spread of cancer. Monoclonal antibodies, such as denosumab, may interfere with the ability of tumor cells to grow and spread. Giving everolimus and anakinra or denosumab may work better in treating participants with advanced cancers.

Condition or Disease	Intervention/Treatment	Phase
Advanced Malignant Neoplasm Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm	Biological: Anakinra Biological: Denosumab Drug: Everolimus	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of anakinra or denosumab in combination with everolimus in patients with advanced cancers who progressed on standard therapy.

SECONDARY OBJECTIVES:

Preliminary assessment of antitumor efficacy of anakinra or denosumab in combination with everolimus in patients with advanced cancers.
Assessment of the pharmacokinetic (PK) profile of anakinra or denosumab in combination with everolimus.
Preliminary assessment of biomarkers.

OUTLINE: This is a dose-escalation study of everolimus. Participants are assigned to 1 of 2 arms.

ARM I: Participants receive everolimus orally (PO) daily and anakinra subcutaneously (SC) daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.

ARM II: Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 days.

Study Design

Study Type:

Interventional

Actual Enrollment :

57 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies

Actual Study Start Date :

Jun 19, 2012

Actual Primary Completion Date :

Feb 24, 2021

Actual Study Completion Date :

Feb 24, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm I (everolimus, anakinra) Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.	Biological: Anakinra Given SC Other Names: Kinaret Kineret rIL-1ra rIL1RN Drug: Everolimus Given PO Other Names: 42-O-(2-Hydroxy)ethyl Rapamycin Afinitor Certican RAD 001 RAD001 Votubia Zortress
Experimental: Arm II (everolimus, denosumab) Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.	Biological: Denosumab Given SC Other Names: AMG 162 AMG-162 Prolia Xgeva Drug: Everolimus Given PO Other Names: 42-O-(2-Hydroxy)ethyl Rapamycin Afinitor Certican RAD 001 RAD001 Votubia Zortress

Arm

Intervention/Treatment

Experimental: Arm I (everolimus, anakinra)

Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.

Biological: Anakinra

Given SC

Other Names:

Kinaret

Kineret

rIL-1ra

rIL1RN

Drug: Everolimus

Given PO

Other Names:

42-O-(2-Hydroxy)ethyl Rapamycin

Afinitor

Certican

RAD 001

RAD001

Votubia

Zortress

Experimental: Arm II (everolimus, denosumab)

Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.

Biological: Denosumab

Given SC

Other Names:

AMG 162

AMG-162

Prolia

Xgeva

Drug: Everolimus

Given PO

Other Names:

42-O-(2-Hydroxy)ethyl Rapamycin

Afinitor

Certican

RAD 001

RAD001

Votubia

Zortress

Outcome Measures

Primary Outcome Measures

Maximum tolerated dose (MTD) of everolimus [At 28 days]
If more than 33% of patients enrolled at any particular dose level develop dose limiting toxicity (DLT), the treatment will continue at the dose level immediately below. If not more than 33% of the patients in the cohort develop DLT, this cohort will be considered the MTD. Only DLTs within course 1 (4 weeks) will be counted with respect to the dose-escalation algorithm.
Incidence of adverse events [Up to 30 days]
Describing the toxicity profile, descriptive statistics will be provided on the grade and type of toxicity by dose level.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with advanced or metastatic cancers that are refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months.
Patients must be >= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment provided that radiation is not delivered to the only site of disease being treated under this protocol. For biologic/targeted agents patients must be >= 5 half-lives or >= 3 weeks form the last dose (whichever comes first).
Eastern Cooperative Oncology Group (ECOG) performance status =< 2.
Absolute neutrophil count (ANC) >= 1,000/mL.
Platelets >= 75,000/mL.
Creatinine clearance >= 35 ml/min.
Total bilirubin =< 2 X upper limit of normal (ULN) (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome). Exception for patients with liver metastasis: total bilirubin =< 3 x ULN.
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) and or aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 5 X ULN. Exception for patients with liver metastasis: ALT (SGPT) =< 8 X ULN.
Fasting lipid profile: cholesterol =< 350 mg/dL.
Fasting lipid profile: triglycerides =< 400 mg/dL.
Corrected calcium >= 8.4 mg/dL.
Phosphorus >= 2.5 mg/dL for denosumab.
Oral examination and appropriate preventive dentistry will be performed prior to the initiation of denosumab therapy.
Negative tuberculosis quantiferon test for anakinra arm.
Negative serology for histoplasma, blastomycosis, and Coccidioidomycosis for anakinra arm.
Negative serology for active hepatitis B and C for anakinra arm. Patients with positive serology for hepatitis B might eligible if they are willing to take lamivudine preventive therapy.
Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
Patients must be able to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

Uncontrolled intercurrent illness, including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support. Treatment of pre-existing invasive fungal infections must be completed prior to starting treatment.
Patients with an active infection.
Pregnant or lactating women.
History of hypersensitivity to anakinra.
History of hypersensitivity to denosumab.
History of hypersensitivity to everolimus.
History of hypersensitivity to any component of the formulation.
Patients unwilling or unable to sign informed consent document.
Patients treated with TNF antagonists.
Patients with a history of active systemic fungal infection.
Patients with liver disease Child Pugh classification B and C.